Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials

  title={Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials},
  author={Amna Majeed and Jiaqi Xiong and Kayla M. Teopiz and Jason Ng and Roger Chun-Man Ho and Joshua D. Rosenblat and Lee Phan and Bing Cao and Roger S. McIntyre},
  journal={Expert Opinion on Emerging Drugs},
  pages={63 - 74}
ABSTRACT Introduction The large percentage of adults with major depressive disorder (MDD) insufficiently responding and/or tolerating conventional monoamine-based antidepressants invites the need for mechanistically novel treatments. Convergent evidence implicates glutamatergic signaling as a potential therapeutic target in MDD. Areas covered The synthesis herein of preclinical and clinical studies indicates that dextromethorphan (DXM) is well tolerated and exhibits clinically significant… 
2 Citations
Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia
The review suggests that antidepressants (ADs) are effective medications and they can be prescribed to correct depressive disorders and negative symptoms in patients with schizophrenia when used in combination with antipsychotics (АPs), however, when administering ADs and АPs combinations, it is important to consider the safety profile of these combinations as well as their tolerance.


Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial.
New targets for rapid antidepressant action
A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder
The results, the first of their kind, indicate that insufflated NPY is antidepressant, despite not meeting the primary outcome, and call for dose ranging and repeated NPY insufflation trials.
Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective
  • K. Hashimoto
  • Biology, Psychology
    Psychiatry and clinical neurosciences
  • 2019
The author reviews the historical overview of the antidepressant actions of enantiomers of ketamine and its major metabolites norketamine and hydroxynorketamines and discusses the other potential rapid‐acting antidepressant candidates to compare them with ketamine.
Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule.
This report appears to be the first report of a rapid-acting effect in unipolar MDD and adds to antidepressant effects observed in the retrospective chart review of 77 patients with Bipolar II Disorder.
Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review
  • M. Pompili, G. Serafini, P. Girardi
  • Psychology, Medicine
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2013
Agomelatine, a melatonergic analogue drug acting as MT1/MT2 agonist and 5-HT2C antagonist, has been reported to be effective as antidepressant drug and enhances neuroplasticity mechanisms and adult neurogenesis in brain areas such as hippocampus and prefrontal cortex.
Mechanism of action of antidepressant medications.
  • J. Feighner
  • Psychology
    The Journal of clinical psychiatry
  • 1999
The new antidepressants, including the single-receptor selective serotonin reuptake inhibitors (SSRIs) and multiple-re receptor antidepressants venlafaxine, mirtazapine, bupropion, trazodone, and nefazodone are discussed.
Jump-starting natural resilience reverses stress susceptibility
The majority of the population successfully employs active coping skills in response to stress, such as optimism, rationalization, wishful thinking, relaxation, and humor, which are linked to the function of the mesolimbic reward neural circuitry, so there is an imperative need for the development of naturally acting antidepressants.
The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS.